Post discharge support is crucial to ensure patients are adherent to their newly prescribed medications. The New medicines service (NMS) was introduced Olaparib molecular weight in October 2011 with the aim of providing support to patients with long term conditions who have been prescribed a new medication. The conditions included are chronic obstructive pulmonary disease, asthma, type 2 diabetes, hypertension and anyone on antiplatelet/anticoagulant therapy. The NMS serves the purpose of providing education and counselling to patients to drive medication adherence. This study aimed to seek community pharmacists’
(CPs) perceptions about NMS and to ascertain the level of referral for this service from secondary care. Two cross sectional self-administrated questionnaire studies were click here undertaken; one directed at patients being discharged from a large teaching hospital within South West (SW) London and the other directed at CPs within two Primary Care Trusts (PCTs) which margin the hospital. Both questionnaires consisted mainly of closed ended and Likert scale questions. The questionnaires were piloted on 5 CPs and 8 patients respectively to ensure face and content validity. 140 questionnaires were distributed to all CPs within the two PCTs, only 52 were completed (37% response rate). The drug charts of recently discharged patients from 3 wards within a period of two weeks in March 2013
were screened to identify those eligible for the NMS service. 56 patients were identified and were given a short questionnaire to seek their awareness of the NMS service and whether they were referred to it. The study was
approved by the academic institution ethics committee. The number of NMS interventions provided monthly by the pharmacists ranged from 1 to 30 with a mean Chlormezanone of 7. Majority of pharmacists (58%, n = 30) specified that most NMS interventions were provided for hypertensive patients with 27% (n = 14) of pharmacists providing the most NMS interventions to asthmatic or COPD patients. Diabetic patients were the third common type of patients provided with an NMS intervention (6%, n = 3). None of the pharmacists surveyed stated providing NMS for patients on anti-coagulants/antiplatelets. The participating pharmacists were asked whether they felt any more training was required to improve NMS provision, 32.7% (n = 17) pharmacists felt that more training was required. The topics of training mostly selected were; drug related (60%, n = 12) and medical condition related (55%, n = 11). Majority of pharmacists (68.6% n = 35) also wanted a structured checklist to be made available for them to support NMS. On average only 2 patients were referred to the NMS monthly from secondary care. From the 56 patients, eligible for the NMS, surveyed, only 9 (16.1%) were aware of the NMS with 3 (5.3%) being referred to it. However, 48 patients (86%) expressed an interest in the service.